Trump picks Azar as health secretary

Pharmaceutical background worries critics; supporters call it an asset


Photographs by AP Photo/Evan Vucci

In this June 8, 2006 file photo, then Deputy Health and Human Services Secretary Alex Azar meets reporters at the HHS Department in Washington. Azar was a top HHS official during the George W. Bush administration.

WASHINGTON -- Turning to an industry he's rebuked both as a candidate and as president, Donald Trump on Monday picked a former top pharmaceutical and government executive to be his health secretary.

If confirmed, Alex Azar would oversee a $1 trillion department responsible for major health insurance programs, including those under the Patient Protection and Affordable Care Act, as well as medical research, food and drug safety, and public health.

The nomination of Azar is unusual because Health and Human Services secretaries have typically come from the ranks of elected officials such as governors, leaders in academia and medicine, or top executive branch managers -- not industries regulated by the department.

"He will be a star for better healthcare and lower drug prices!" Trump tweeted in a morning announcement. Trump has a track record of making industry-friendly nominations, such as former Exxon Mobil CEO Rex Tillerson as secretary of state and wealthy investor Wilbur Ross as secretary of commerce.

[PRESIDENT TRUMP: Timeline, appointments, executive orders + guide to actions in first 200 days]

Azar, 50, a lawyer by training, has spent most of the past 10 years with pharmaceutical giant Eli Lilly, rising to president of its key U.S. affiliate before leaving in January to start his own consulting firm. He's also seen as an expert on government health care regulation.

As secretary, Azar would be returning to the Health and Human Services Department after serving in senior posts in the George W. Bush administration. He would have to scrupulously avoid conflicts with Lilly's far-reaching interests, including drug approval and Medicare reimbursement. The drugmaker has drawn criticism from patient advocacy groups for price increases to one of its biggest products: insulin, used to treat high blood sugar for nearly 100 years.

Azar's earlier nominations in the Bush era sailed through the Senate. This time, he'll face Democrats wary of the administration's quest to repeal the Affordable Care Act.

Top Democrats in Congress were skeptical but also said they hoped Azar would bring a shift from an ideological hard line on the health care law.

"It's time to turn over a new leaf at HHS," said Sen. Charles Schumer of New York, the Democratic leader.

Sen. Patty Murray, D-Wash., flagged a potential conflict of interest, questioning how Azar "can fairly execute any significant effort to lower drug prices for patients." Murray is the senior Democrat on the Health, Education, Labor and Pensions Committee.

But committee Chairman Sen. Lamar Alexander, R-Tenn., cast Azar as a problem solver, saying "he has the qualifications and experience to get results."

Insurers and for-profit hospitals also reacted positively, but the Public Citizen advocacy group likened Azar's nomination to a "coup d'etat" by drug companies.

Americans consistently rank the high cost of prescription drugs among their top health care priorities, ahead of divisive issues like repealing former President Barack Obama's health care law.

Trump has been a sharp critic of the industry. "The drug companies, frankly, are getting away with murder," he said at a Cabinet meeting this fall, adding that prices are "out of control."

In the spring, Trump sent drug stocks tumbling after saying he was working on a new system that would foster competition and lead to much lower prices. In meetings with industry executives, however, Trump has focused on speeding up drug approvals, a cost-reducing tactic they would back.

If confirmed, Azar would join the club of Trump administration officials from big business. Ross was chairman of a private equity firm he founded and later sold. Treasury Secretary Steven Mnuchin was a former Goldman Sachs executive and hedge fund manager. Tillerson was CEO of Exxon Mobil.

Admirers say Azar's drug industry experience should be considered an asset, not a liability.

"To the extent that the Trump administration has talked about lowering drug prices, here's a guy who understands how it works," said Tevi Troy, who served with Azar in the Bush administration and now leads the American Health Policy Institute, a think tank focused on employer health insurance.

"Would [Azar] have been better off if he had been meditating in an ashram after serving as deputy secretary?" asked Troy.

Azar would be Trump's second Health and Human Services secretary, replacing former Rep. Tom Price of Georgia, who resigned after his use of private charter planes for government travel displeased the president.

Information for this article was contributed by Matthew Perrone and Tom Murphy of The Associated Press.

A Section on 11/14/2017

Log in to comment